INTS INTENSITY THERAPEUTICS, INC.

Nasdaq intensitytherapeutics.com


$ 0.39 $ -0.03 (-7.3 %)    

Tuesday, 11-Nov-2025 17:22:11 EST
QQQ $ 622.49 $ 0.90 (0.15 %)
DIA $ 479.63 $ 5.34 (1.13 %)
SPY $ 683.37 $ 2.90 (0.43 %)
TLT $ 89.91 $ 0.01 (0.01 %)
GLD $ 380.58 $ -0.09 (-0.02 %)
$ 0.39
$ 0.42
$ 0.37 x 200
$ 0.42 x 230
$ 0.38 - $ 0.42
$ 0.19 - $ 3.40
3,814,178
na
23.43M
$ -0.23
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 03-13-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-14-2024 12-31-2023 10-K
9 11-13-2023 09-30-2023 10-Q
10 08-14-2023 06-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 intensity-therapeutics-stock-cools-after-hours-following-395-surge-what-you-should-know

Intensity Therapeutics shares plunged 31.9% after-hours following the publication of Phase 1/2 trial results for its cancer the...

 intensity-therapeutics-reports-early-radiological-and-pathological-results-with-int230-6-demonstrating-high-drug-absorption-tumor-necrosis-and-evidence-of-immune-activation

A pathological complete response ("pCR") has been observed in the first patient evaluated in Cohort A, where each patie...

 benchmark-maintains-speculative-buy-on-intensity-therapeutics-lowers-price-target-to-15

Benchmark analyst Robert Wasserman maintains Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and lowers the pric...

 brookline-capital-upgrades-intensity-therapeutics-to-buy-announces-3-price-target

Brookline Capital analyst Kumaraguru Raja upgrades Intensity Therapeutics (NASDAQ:INTS) from Hold to Buy and announces $3 pr...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION